Final answer:
Platelet glycoprotein IIB/IIA receptor inhibitors inhibit platelet aggregation by preventing fibrinogen from binding to platelets, thus blocking the formation of arterial thrombi(option b).
Step-by-step explanation:
Platelet glycoprotein IIB/IIA receptor inhibitors play a crucial role in the control of platelet aggregation. These inhibitors target the glycoprotein IIB/IIA receptors on the surface of platelets, which are essential for platelet aggregation. By inhibiting these receptors, the drugs prevent fibrinogen from binding to platelets, effectively blocking platelet aggregation. This is particularly important in the prevention of arterial thrombosis. Therefore, the correct answer to the question is b. Inhibit platelet aggregation.
It is interesting to note that while prostaglandins can induce vasoconstriction, other chemicals like nitric oxide and adenosine are known to cause vasodilation. However, this mechanism is distinct from the function of glycoprotein IIB/IIA receptor inhibitors. Understanding the role of these receptors and inhibitors in the cardiovascular system can help in the management of conditions such as acute coronary syndrome, where prevention of clot formation is critical.